The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis

Leiper, J. and Nandi, M. (2011) The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nature Reviews Drug Discovery, 10(4), pp. 277-291. (doi: 10.1038/nrd3358) (PMID:21455237)

Full text not currently available from Enlighten.


Asymmetric dimethylarginine (ADMA) — a naturally occurring amino acid that is a product of protein breakdown — is released into the cytoplasm following the post-translational methylation of arginine residues within proteins and the subsequent proteolysis of these arginine-methylated proteins. ADMA inhibits all three isoforms of nitric oxide synthase and therefore has the potential to produce diverse biological effects, particularly in the cardiovascular system. In addition to its renal clearance, endogenously produced ADMA is metabolized to L-citrulline and dimethylamine by the dimethylarginine dimethylaminohydrolase (DDAH) enzymes. Pharmacological modification of DDAH has therefore been proposed as a mechanism for manipulating endogenous ADMA concentrations and regulating the production of nitric oxide in situations where alterations in nitric oxide signalling have been shown to contribute to pathophysiology. This Review describes the biology of ADMA and the potential therapeutic utility of manipulating DDAH activity.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Leiper, Professor James
Authors: Leiper, J., and Nandi, M.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Nature Reviews Drug Discovery
Publisher:Nature Publishing Group
ISSN (Online):1474-1784
Published Online:01 April 2011

University Staff: Request a correction | Enlighten Editors: Update this record